James Lovgren - MaxCyte VP Marketing
| MXCT Stock | USD 3.07 0.20 6.12% |
Insider
James Lovgren is VP Marketing of MaxCyte
| Phone | 301 944 1700 |
| Web | https://www.maxcyte.com |
MaxCyte Management Efficiency
The company has return on total asset (ROA) of (0.126) % which means that it has lost $0.126 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1873) %, meaning that it created substantial loss on money invested by shareholders. MaxCyte's management efficiency ratios could be used to measure how well MaxCyte manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA BS | Sight Sciences | N/A | |
| Matt Garner | Iradimed Co | N/A | |
| Mark Quick | Orthofix Medical | N/A | |
| Bart Bracy | Anika Therapeutics | N/A | |
| Elizabeth Giddens | Integer Holdings Corp | 49 | |
| John Wilson | Rapid Micro Biosystems | 57 | |
| John Liu | Sight Sciences | N/A | |
| Stacie Rodgers | Sight Sciences | N/A | |
| BA Chemistry | Orthofix Medical | 63 | |
| Jonathan Paris | Rapid Micro Biosystems | 48 | |
| Lisa Paul | Pulmonx Corp | 61 | |
| Mark Saxton | Neuropace | 59 | |
| Anne Nunes | Anika Therapeutics | 55 | |
| Laverne Council | CONMED | 59 | |
| Sam Park | Sight Sciences | 63 | |
| David Colleran | Anika Therapeutics | 52 | |
| Reay Brown | Sight Sciences | N/A | |
| Shanna Cottiosmanski | CONMED | 48 | |
| Derrick Sung | Pulmonx Corp | 51 | |
| John Ordway | Sight Sciences | N/A | |
| Charles III | Anika Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.19 | ||||
| Return On Asset | -0.13 |
MaxCyte Leadership Team
Elected by the shareholders, the MaxCyte's board of directors comprises two types of representatives: MaxCyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MaxCyte. The board's role is to monitor MaxCyte's management team and ensure that shareholders' interests are well served. MaxCyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MaxCyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Brady, Senior Support | ||
| Stark Thompson, Consultant | ||
| Jill Mayer, Senior Resources | ||
| Cenk Sumen, Chief Officer | ||
| Douglas Doerfler, President, Founder | ||
| Jay Gelfman, Senior Operations | ||
| David Sandoval, General President | ||
| Thomas Ross, Executive Marketing | ||
| AnaPaula Fernandes, Senior Sales | ||
| Ronald CPA, Executive Administration | ||
| Jack Horgan, Vice Development | ||
| Ali Soleymannezhad, Chief Officer | ||
| Sarah Meeks, Senior Development | ||
| James Lovgren, VP Marketing | ||
| Maher Masoud, CEO, President | ||
| Sean Menarguez, Director Relations | ||
| CPA CFA, Chief Officer |
MaxCyte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MaxCyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.19 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (1.06) % | ||||
| Operating Margin | (1.48) % | ||||
| Current Valuation | 207.71 M | ||||
| Shares Outstanding | 106.03 M | ||||
| Shares Owned By Insiders | 1.48 % | ||||
| Shares Owned By Institutions | 74.24 % | ||||
| Number Of Shares Shorted | 2.77 M | ||||
| Price To Book | 1.68 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.